Follow The Filings

DAFNA Capital Management LLC Nathan Fischel

Los Angeles, CA 20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $524M
  • 88 holdings
  • 2026 Q2
  • +19.1% QoQ
  • Top 5 40.2%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 88 holdings

Top 5 40.2%, top 10 56.2%

  1. RVMD, Revolution Medicines 20.1%
  2. XBI, SPDR S&P Biotech ETF 5.9%
  3. CMPS, Compass Pathways 5.4%
  4. STXS, Stereotaxis 4.5%
  5. NKTR, Nektar Therapeutics 4.3%
  6. DNLI, Denali Therapeutics 3.6%
  7. IDYA, Ideaya Biosciences 3.5%
  8. ATRC, Atricure 3.2%
  9. XENE, Xenon Pharmaceuticals 2.9%
  10. CYTK, Cytokinetics 2.8%
  11. RCUS, Arcus Biosciences 2.6%
  12. ASND, Ascendis Pharma A/s 2.5%
  13. Other 38.7%

AUM over time

2026 Q2 $524M +19.1% QoQ
2021 Q3: $377M 2021 Q3: $377M
Q3 2021
2021 Q4: $398M, +5.6% QoQ 2021 Q4: $398M, +5.6% QoQ
Q4
2022 Q1: $384M, −3.5% QoQ 2022 Q1: $384M, −3.5% QoQ
Q1 2022
2022 Q2: $367M, −4.4% QoQ 2022 Q2: $367M, −4.4% QoQ
Q2
2022 Q3: $372M, +1.4% QoQ 2022 Q3: $372M, +1.4% QoQ
Q3
2022 Q4: $355M, −4.6% QoQ 2022 Q4: $355M, −4.6% QoQ
Q4
2023 Q1: $334M, −5.9% QoQ 2023 Q1: $334M, −5.9% QoQ
Q1 2023
2023 Q2: $366M, +9.6% QoQ 2023 Q2: $366M, +9.6% QoQ
Q2
2023 Q3: $321M, −12.3% QoQ 2023 Q3: $321M, −12.3% QoQ
Q3
2023 Q4: $417M, +29.9% QoQ 2023 Q4: $417M, +29.9% QoQ
Q4
2024 Q1: $439M, +5.3% QoQ 2024 Q1: $439M, +5.3% QoQ
Q1 2024
2024 Q2: $419M, −4.6% QoQ 2024 Q2: $419M, −4.6% QoQ
Q2
2024 Q3: $423M, +1.0% QoQ 2024 Q3: $423M, +1.0% QoQ
Q3
2024 Q4: $393M, −7.1% QoQ 2024 Q4: $393M, −7.1% QoQ
Q4
2025 Q1: $353M, −10.2% QoQ 2025 Q1: $353M, −10.2% QoQ
Q1 2025
2025 Q2: $362M, +2.5% QoQ 2025 Q2: $362M, +2.5% QoQ
Q2
2025 Q3: $405M, +11.9% QoQ 2025 Q3: $405M, +11.9% QoQ
Q3
2025 Q4: $431M, +6.4% QoQ 2025 Q4: $431M, +6.4% QoQ
Q4
2026 Q1: $440M, +2.1% QoQ 2026 Q1: $440M, +2.1% QoQ
Q1 2026
2026 Q2: $524M, +19.1% QoQ 2026 Q2: $524M, +19.1% QoQ
Q2

Book

2021 Q3, filed 15 Nov, long equity only

Download CSV Download Excel
STXS, Stereotaxis 19.53% Hold 13,680,554 $5.38 $74M
Blueprint Medicines 5.64% Hold 206,911 $102.81 $21M
FATE, Fate Therapeutics 5.41% Hold 344,360 $59.27 $20M
BHVN, Biohaven 3.25% Hold 88,100 $138.91 $12M
Dicerna Pharmaceuticals 3.14% Hold 587,456 $20.16 $12M
IDYA, Ideaya Biosciences 3.11% Hold 460,061 $25.49 $12M
DXCM, DexCom 3.07% Hold 21,138 $546.88 $12M
Morphic 2.73% Hold 181,467 $56.64 $10M
NRIX, Nurix Therapeutics 2.43% Hold 306,320 $29.96 $9.2M
Karuna Therapeutics 2.42% Hold 74,585 $122.33 $9.1M
NBIX, Neurocrine Biosciences 2.15% Hold 84,655 $95.91 $8.1M
Sage Therapeutics 2.12% Hold 180,306 $44.31 $8M
Arena Pharmaceuticals 1.89% Hold 119,615 $59.55 $7.1M
NDAQ, iShares Trust Nasdaq Biotech 1.75% Hold 40,900 $161.69 $6.6M
Cardiovascular Systems 1.69% Hold 193,741 $32.83 $6.4M
CYTK, Cytokinetics 1.66% Hold 175,000 $35.74 $6.3M
XENE, Xenon Pharmaceuticals 1.65% Hold 406,535 $15.28 $6.2M
Affimed 1.58% Hold 964,857 $6.18 $6M
RVMD, Revolution Medicines 1.53% Hold 209,731 $27.51 $5.8M
F-Star Therapeutics 1.35% Hold 693,785 $7.32 $5.1M
ATRC, Atricure 1.33% Hold 72,029 $69.56 $5M
Otonomy 1.21% Hold 2,379,392 $1.92 $4.6M
RCUS, Arcus Biosciences 1.14% Hold 123,700 $34.87 $4.3M
LKFT, Galapagos 1.08% Hold 77,675 $52.60 $4.1M
ARAY, Accuray 0.99% Hold 941,800 $3.95 $3.7M
Iveric Bio 0.93% Hold 216,351 $16.24 $3.5M
Kalvista Pharmaceuticals 0.88% Hold 189,163 $17.45 $3.3M
Aerie Pharmaceuticals 0.87% Hold 289,040 $11.40 $3.3M
FS Development Corporation II 0.79% Hold 299,950 $9.95 $3M
Adicet Bio 0.78% Hold 376,281 $7.84 $3M
Rigel Pharmaceuticals 0.78% Hold 809,000 $3.63 $2.9M
Merus 0.77% Hold 131,949 $22.00 $2.9M
VKTX, Viking Therapeutics 0.75% Hold 447,400 $6.28 $2.8M
Venus Concept 0.74% Hold 1,113,228 $2.51 $2.8M
Holding 0.74% Hold 41,952 $66.43 $2.8M
Kadmon 0.73% Hold 314,561 $8.71 $2.7M
Mereo Biopharma Group 0.72% Hold 1,126,613 $2.42 $2.7M
89bio 0.66% Hold 126,652 $19.59 $2.5M
PRQR, Proqr Therapeutics 0.66% Hold 296,383 $8.37 $2.5M
ALEC, Alector 0.65% Hold 107,412 $22.82 $2.5M
Kinnate Biopharma 0.65% Hold 106,453 $23.02 $2.5M
Natus Medical 0.64% Hold 95,653 $25.08 $2.4M
Iteos Therapeutics 0.60% Hold 83,061 $27.00 $2.2M
Neuronetics 0.55% Hold 313,717 $6.56 $2.1M
IPSC, Century Therapeutics 0.53% Hold 80,000 $25.16 $2M
Cymabay Therapeutics 0.51% Hold 524,286 $3.65 $1.9M
Holding 0.50% Hold 322,124 $5.89 $1.9M
KURA, Kura Oncology 0.50% Hold 100,829 $18.73 $1.9M
Macrogenics 0.50% Hold 90,000 $20.94 $1.9M
COGT, Cogent Biosciences 0.50% Hold 223,554 $8.41 $1.9M

Showing top 50 of 78 by value

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 88 $524M +19.1% 13F-HR 8/14/2026 000138993326000006
2026 Q1 83 $440M +2.1% 13F-HR 5/15/2026 000138993326000004
2025 Q4 77 $431M +6.4% 13F-HR 2/17/2026 000138993326000002
2025 Q3 75 $405M +11.9% 13F-HR 11/14/2025 000138993325000008
2025 Q2 76 $362M +2.5% 13F-HR 8/14/2025 000138993225000011
2025 Q1 83 $353M −10.2% 13F-HR 5/15/2025 000138993325000002
2024 Q4 82 $393M −7.1% 13F-HR 2/14/2025 000138993225000004
2024 Q3 84 $423M +1.0% 13F-HR 11/14/2024 000138993224000020
2024 Q2 83 $419M −4.6% 13F-HR 8/14/2024 000138993224000016
2024 Q1 72 $439M +5.3% 13F-HR 5/15/2024 000138993224000012
2023 Q4 76 $417M +29.9% 13F-HR 2/14/2024 000138993224000004
2023 Q3 75 $321M −12.3% 13F-HR 11/14/2023 000138993223000010
2023 Q2 73 $366M +9.6% 13F-HR 8/14/2023 000138993323000008
2023 Q1 72 $334M −5.9% 13F-HR 5/15/2023 000138993323000006
2022 Q4 79 $355M −4.6% 13F-HR 2/14/2023 000138993323000002
2022 Q3 87 $372M +1.4% 13F-HR 11/14/2022 000138993322000010
2022 Q2 90 $367M −4.4% 13F-HR 8/15/2022 000138993322000008
2022 Q1 94 $384M −3.5% 13F-HR 5/16/2022 000138993322000006
2021 Q4 87 $398M +5.6% 13F-HR 2/14/2022 000138993322000002
2021 Q3 80 $377M — 13F-HR 11/15/2021 000138993321000011

About

DAFNA Capital Management LLC

20 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
DAFNA Capital Management LLC
Notable person
Nathan Fischel
Location
Los Angeles, CA
All SEC filings
View on sec.gov